A pilot trial of oral topotecan for the treatment of refractory advanced solid neoplasms expressing HIF-1 alpha [hypoxia inducible factor 1 alpha]
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Topotecan (Primary)
- Indications Solid tumours
- Focus Pharmacodynamics
- 02 Jul 2017 Biomarkers information updated
- 28 Sep 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 Sep 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.